Interventional cardiology: Operator technique is predictive of BVS-related adverse events

Comment

Karina Huynh. Nat Rev Cardiol. 2018 Feb.

. 2018 Feb;15(2):67.

doi: 10.1038/nrcardio.2017.217. Epub 2017 Dec 21.

No abstract available

Comment on

3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds: The ABSORB III Trial.
Kereiakes DJ, Ellis SG, Metzger C, Caputo RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, Marx SO, Popma JJ, McGreevy R, Zhang Z, Simonton C, Stone GW; ABSORB III Investigators. Kereiakes DJ, et al. J Am Coll Cardiol. 2017 Dec 12;70(23):2852-2862. doi: 10.1016/j.jacc.2017.10.010. Epub 2017 Oct 31. J Am Coll Cardiol. 2017. PMID: 29100702 Clinical Trial.
Effect of Technique on Outcomes Following Bioresorbable Vascular Scaffold Implantation: Analysis From the ABSORB Trials.
Stone GW, Abizaid A, Onuma Y, Seth A, Gao R, Ormiston J, Kimura T, Chevalier B, Ben-Yehuda O, Dressler O, McAndrew T, Ellis SG, Kereiakes DJ, Serruys PW. Stone GW, et al. J Am Coll Cardiol. 2017 Dec 12;70(23):2863-2874. doi: 10.1016/j.jacc.2017.09.1106. Epub 2017 Oct 31. J Am Coll Cardiol. 2017. PMID: 29100704 Clinical Trial.